122 related articles for article (PubMed ID: 3069943)
41. [Preclinical and clinical evaluation of toxicity and antitumor activity of cisplatin analogues].
Ariyoshi Y; Ota K
Gan To Kagaku Ryoho; 1989 Apr; 16(4 Pt 2-2):1379-85. PubMed ID: 2658826
[TBL] [Abstract][Full Text] [Related]
42. Antitumor activity of imidazothioxanthones in murine and human tumor models in vitro and in vivo.
Varvaresou A; Iakovou K; Gikas E; Fichtner I; Fiebig HH; Kelland LR; Double JA; Bibby MC; Hendriks HR
Anticancer Res; 2004; 24(2B):907-19. PubMed ID: 15161044
[TBL] [Abstract][Full Text] [Related]
43. Synthesis, cytotoxicity and antitumor activity of platinum(II) complexes of cyclopentanecarboxylic acid hydrazide.
Kushev D; Gorneva G; Taxirov S; Spassovska N; Grancharov K
Biol Chem; 1999 Nov; 380(11):1287-94. PubMed ID: 10614821
[TBL] [Abstract][Full Text] [Related]
44. Schedule dependency of orally administered bis-acetato-ammine-dichloro-cyclohexylamine-platinum(IV) (JM216) in vivo.
McKeage MJ; Kelland LR; Boxall FE; Valenti MR; Jones M; Goddard PM; Gwynne J; Harrap KR
Cancer Res; 1994 Aug; 54(15):4118-22. PubMed ID: 8033145
[TBL] [Abstract][Full Text] [Related]
45. Antitumor efficacy of nedaplatin, a novel platinum complex, with cyclophosphamide in murine and human tumor model.
Uchida N; Takeda Y; Kasai H; Maekawa R; Sugita K; Yoshioka T
Anticancer Res; 1998; 18(5A):3375-9. PubMed ID: 9858911
[TBL] [Abstract][Full Text] [Related]
46. Antitumor activity of cis-malonato[(4R,5R)-4,5-bis(aminomethyl)-2- isopropyl-1,3-dioxolane]platinum(II), a new platinum analogue, as an anticancer agent.
Kim DK; Kim HT; Cho YB; Tai JH; Ahn JS; Kim TS; Kim KH; Hong WS
Cancer Chemother Pharmacol; 1995; 35(5):441-5. PubMed ID: 7850928
[TBL] [Abstract][Full Text] [Related]
47. Preclinical activity of lobaplatin as a single agent and in combination with taxanes for ovarian carcinoma cells.
Sun X; Lou LG; Sui DH; Wu XH
Asian Pac J Cancer Prev; 2014; 15(22):9939-43. PubMed ID: 25520132
[TBL] [Abstract][Full Text] [Related]
48. Comparison of the antitumor activity of cisplatin, carboplatin, and iproplatin against established human testicular cancer cell lines in vivo and in vitro.
Harstrick A; Casper J; Guba R; Wilke H; Poliwoda H; Schmoll HJ
Cancer; 1989 Mar; 63(6):1079-83. PubMed ID: 2645036
[TBL] [Abstract][Full Text] [Related]
49. [Cytokinetic effects of carboplatin and cisplatin on a human ovarian cancer cell line].
Yoshizumi N; Fujiwara J; Yoshizaki A; Sato M; Sakai R; Nishiya I
Hum Cell; 1988 Sep; 1(3):301-7. PubMed ID: 2979207
[TBL] [Abstract][Full Text] [Related]
50. Human ovarian-carcinoma cell lines and companion xenografts: a disease-oriented approach to new platinum anticancer drug discovery.
Kelland LR; Jones M; Abel G; Valenti M; Gwynne J; Harrap KR
Cancer Chemother Pharmacol; 1992; 30(1):43-50. PubMed ID: 1586979
[TBL] [Abstract][Full Text] [Related]
51. Preclinical activity of a new platinum analogue, lobaplatin, in cisplatin-sensitive and -resistant human testicular, ovarian, and gastric carcinoma cell lines.
Harstrick A; Bokemeyer C; Scharnofkse M; Hapke G; Reile D; Schmoll HJ
Cancer Chemother Pharmacol; 1993; 33(1):43-7. PubMed ID: 8269588
[TBL] [Abstract][Full Text] [Related]
52. Characterization of newly established cell line HUOA from a human ovarian serous cystadenocarcinoma.
Ishiwata I; Ishiwata C; Kobayashi N; Ishikawa H
Nihon Sanka Fujinka Gakkai Zasshi; 1987 May; 39(5):831-6. PubMed ID: 3598277
[TBL] [Abstract][Full Text] [Related]
53. In vitro phase II comparison of the cytotoxicity of a novel platinum analog, nedaplatin (254-S), with that of cisplatin and carboplatin against fresh, human ovarian cancers.
Alberts DS; Fanta PT; Running KL; Adair LP; Garcia DJ; Liu-Stevens R; Salmon SE
Cancer Chemother Pharmacol; 1997; 39(6):493-7. PubMed ID: 9118460
[TBL] [Abstract][Full Text] [Related]
54. [Biological properties of two newly established cell lines (RMUG-S, RMUG-L) from a human ovarian mucinous cystadenocarcinoma].
Sakayori M; Nozawa S; Udagawa Y; Chin K; Lee SG; Sakuma T; Iizuka R; Wada Y; Yoshida S; Takeda Y
Hum Cell; 1990 Mar; 3(1):52-6. PubMed ID: 2083224
[TBL] [Abstract][Full Text] [Related]
55. Poly (γ, L-glutamic acid)-cisplatin bioconjugate exhibits potent antitumor activity with low toxicity: a comparative study with clinically used platinum derivatives.
Feng Z; Lai Y; Ye H; Huang J; Xi XG; Wu Z
Cancer Sci; 2010 Nov; 101(11):2476-82. PubMed ID: 20813014
[TBL] [Abstract][Full Text] [Related]
56. [Establishment of a cisplatin-resistant human ovarian cancer cell line and the mechanism of resistance].
Kikuchi Y; Iwano I; Miyauchi M; Kita T; Kizawa I; Oomori K; Kato K
Nihon Sanka Fujinka Gakkai Zasshi; 1988 Mar; 40(3):379-83. PubMed ID: 3361190
[TBL] [Abstract][Full Text] [Related]
57. [Antitumor effect of PSK and its combined effect with CDDP on ovarian serous adenocarcinoma-bearing nude mice].
Ishii K; Kita T; Hirata J; Tode T; Kikuchi Y; Nagata I
Nihon Sanka Fujinka Gakkai Zasshi; 1993 Apr; 45(4):333-9. PubMed ID: 8509669
[TBL] [Abstract][Full Text] [Related]
58. Advantages in combination chemotherapy using cisplatin and its analogues for human testicular tumor xenografts.
Hida S; Okada K; Yoshida O
Jpn J Cancer Res; 1990 Apr; 81(4):425-30. PubMed ID: 2114395
[TBL] [Abstract][Full Text] [Related]
59. The establishment, characterization and calibration of human ovarian carcinoma xenografts for the evaluation of novel platinum anticancer drugs.
Harrap KR; Jones M; Siracky J; Pollard LA; Kelland LR
Ann Oncol; 1990; 1(1):65-76. PubMed ID: 2078487
[TBL] [Abstract][Full Text] [Related]
60. [An experimental study of cisplatin and it's antidote, sodium thiosulfate, in ovarian pseudomyxoma implanted into nude mice abdominal cavity].
Miyahara K; Miyoshi T; Kobayashi H; Hamai J; Tomoo Y; Yamada T; Nishimura H; Yakushiji M; Kato T
Nihon Sanka Fujinka Gakkai Zasshi; 1986 Jul; 38(7):1066-70. PubMed ID: 3746025
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
